
Commentary|Articles|October 7, 2026
- Pharmaceutical Executive: October 2026
- Volume 46
- Issue 8
Why Pharma’s Next Communications Model Won’t Be a Cascade
Author(s)Kishan Rees, M.D.
How the proposed lateral network can change the traditional mindset around communications and pharma’s role in today’s new flow of health information.
Advertisement
Advertisement
In my
Related to this article

Sustainable competitive advantage requires combining proprietary evidence, AI, and human expertise—not substituting one for another.

FDA is requiring manufacturers of all GLP-1 receptor agonists to add a warning for a potential increased risk of NAION.

argenx acquires Unnatural Products, adding a macrocyclic peptide discovery platform to complement its antibody engineering.

FDA approves three new therapies, a wave of dealmaking led by Johnson & Johnson, Eli Lilly, AmyriAD Therapeutics, and Sanofi, and Ossium Health’s Kevin Caldwell joins The Ron Lanton Report on rebuilding bone marrow transplants around deceased-donor marrow.

New deals this week span across ophthalmology to Alzheimer’s, with three new acquisitions and one research collaboration.

Ossium Health’s Kevin Caldwell joins The Ron Lanton Report to explain how banked, deceased-donor marrow is replacing a months-long search for a living donor with a product hospitals can order on demand.
Advertisement
Advertisement


